Syndax Pharmaceuticals’ (SNDX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in a research report report published on Friday morning, Benzinga reports. They currently have a $41.00 target price on the stock.

A number of other analysts also recently commented on the company. StockNews.com upgraded Syndax Pharmaceuticals to a sell rating in a research report on Friday, January 19th. Scotiabank cut Syndax Pharmaceuticals from a sector outperform rating to a sector perform rating and reduced their target price for the stock from $36.00 to $23.00 in a research report on Wednesday, January 31st. Finally, JPMorgan Chase & Co. lifted their price target on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an overweight rating in a research note on Wednesday, March 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals has an average rating of Moderate Buy and an average target price of $34.42.

Syndax Pharmaceuticals Stock Up 1.0 %

Shares of NASDAQ:SNDX opened at $21.28 on Friday. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -7.19 and a beta of 1.03. The business has a 50 day moving average price of $22.64 and a 200 day moving average price of $19.72. Syndax Pharmaceuticals has a twelve month low of $11.22 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same period last year, the business posted ($0.62) EPS. Analysts anticipate that Syndax Pharmaceuticals will post -3.7 EPS for the current year.

Institutional Trading of Syndax Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 97.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company’s stock worth $26,000 after acquiring an additional 880 shares in the last quarter. CWM LLC raised its position in Syndax Pharmaceuticals by 415.3% in the 4th quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after purchasing an additional 1,358 shares during the last quarter. MeadowBrook Investment Advisors LLC acquired a new position in Syndax Pharmaceuticals in the fourth quarter worth $37,000. Quadrant Capital Group LLC boosted its stake in Syndax Pharmaceuticals by 158.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock worth $53,000 after purchasing an additional 1,496 shares in the last quarter. Finally, Annandale Capital LLC bought a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $67,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).